Stifel Financial Corp Has $94,000 Stock Holdings in Altimmune, Inc. (NASDAQ:ALT)

Stifel Financial Corp cut its stake in Altimmune, Inc. (NASDAQ:ALT) by 26.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,103 shares of the company’s stock after selling 4,649 shares during the period. Stifel Financial Corp’s holdings in Altimmune were worth $94,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ALT. SBI Securities Co. Ltd. acquired a new position in shares of Altimmune during the 4th quarter worth $45,000. Cullen Frost Bankers Inc. acquired a new position in shares of Altimmune during the 4th quarter worth $72,000. 180 Wealth Advisors LLC acquired a new position in shares of Altimmune during the 4th quarter worth $78,000. KLP Kapitalforvaltning AS acquired a new position in shares of Altimmune during the 4th quarter worth $81,000. Finally, Raymond James Financial Inc. acquired a new position in shares of Altimmune during the 4th quarter worth $88,000. 78.05% of the stock is owned by institutional investors and hedge funds.

Altimmune Stock Up 1.4%

ALT stock opened at $5.78 on Friday. Altimmune, Inc. has a twelve month low of $3.55 and a twelve month high of $11.16. The stock’s 50 day moving average is $5.10 and its 200-day moving average is $6.58. The firm has a market capitalization of $445.14 million, a PE ratio of -3.73 and a beta of 1.13.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.09. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. During the same period last year, the business posted ($0.34) earnings per share. On average, equities research analysts anticipate that Altimmune, Inc. will post -1.35 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Gregory L. Weaver purchased 10,000 shares of Altimmune stock in a transaction dated Thursday, March 13th. The stock was bought at an average cost of $5.20 per share, for a total transaction of $52,000.00. Following the completion of the transaction, the chief financial officer now owns 10,000 shares in the company, valued at $52,000. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.10% of the company’s stock.

Wall Street Analysts Forecast Growth

ALT has been the subject of a number of research analyst reports. William Blair reissued a “market perform” rating on shares of Altimmune in a report on Friday, March 14th. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Altimmune in a report on Thursday, April 3rd. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $20.20.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.